RELEASED DATE: May 31, 2024
EXPIRATION DATE: May 31, 2025

This educational activity is designed to answer your questions about selecting a first-line immune checkpoint inhibitor-based regimen for your patients with metastatic non-small cell lung cancer that does not harbor a driver alteration. This educational experience incorporates didactic presentation, illustrative animations, and case-based discussions to provide perspectives on the latest clinical trial data and practice guidelines. This program focuses on tailored treatment planning that incorporates the multidisciplinary team with shared decision making, while addressing the management of immune-related adverse events.

This podcast series is designed to answer your questions about selecting and using a first-line immune checkpoint inhibitor-based regimen for your patients with metastatic non-small cell lung cancer that does not harbor a driver gene alteration. During the first podcast, Dr Edward Garon reviews and shares perspectives on current evidence-based practice guidelines for this setting, as well as relevant supporting phase 3 clinical trial data. Additionally, he shares how he approaches clinical areas of uncertainty. In the second podcast, the conversation shifts to best practices for helping your patients get through ICI-based therapy as safely and efficaciously as possible.

RELEASED DATE: June 14, 2024
EXPIRATION DATE: June 21, 2025

This enduring activity will review mechanisms of action of immune checkpoint inhibitors (ICIs), the rationale for their use in combination with chemotherapy to treat metastatic, non-driver-mutated, non-small cell lung cancer (NSCLC), and common immune-related adverse events (irAEs) associated with these agents. This activity incorporates didactic presentation, illustrative animations, and case-based discussion. Throughout the program, expert faculty will guide you through relevant clinical trial data and current clinical practice guidelines, while sharing best practices for irAE management and optimal use of frontline ICI-based therapy.

RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025